Fri, Mar 6, 2015, 7:27 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

  • bluecheese4u bluecheese4u Oct 24, 2012 7:15 AM Flag

    Lilly Reports Third-Quarter 2012 Results

    Lilly Reports Third-Quarter 2012 Results

    INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ --

    •Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations.
    •Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.
    •Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge).
    •Data read-outs provided a better understanding of several potential new medicines in Lilly's clinical pipeline.
    •2012 non-GAAP EPS guidance reconfirmed to be in the range of $3.30 - $3.40, while reported EPS guidance range revised to $3.68 - $3.78.

    Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2012.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
68.41-2.18(-3.09%)Mar 6 4:02 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.